Loading
Everything OnCo dates to 2026: 739 entries, 151 papers, 143 financing rounds, 127 regulatory events and 81 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
739 dated entries in OnCo fall in 2026: 151 papers, 143 financing rounds, 127 regulatory events, 81 trials reported, 76 approvals, 70 landmarks, 54 expected dates, 32 papers listed on people's pages, 2 companies founded, 2 technologies and 1 guideline change.
Of those, 144 to the day, 18 to the month, 17 to the quarter and 560 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Fixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)
Adults with haematological malignancies undergoing matched-donor haematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologi...
Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with lazertinib.
Untreated advanced non-small-cell lung cancer with an activating EGFR exon 20 insertion, with carboplatin and pemetrexed.
Risk stratification in early-stage HR+/HER2- invasive breast cancer
With a fluoropyrimidine and oxaliplatin, adjuvant treatment of stage III dMMR colon cancer (FDA, 8 October 2026)
Adjuvant muscle-invasive bladder cancer, ctDNA-positive after cystectomy
Aumseqa: first-line advanced NSCLC with EGFR exon 19 deletion or L858R; advanced EGFR T790M-positive NSCLC (authorised February 2026; authorisation revoked September 2026)
Adjuvant clear-cell RCC with pembrolizumab
First- and second-line metastatic colorectal cancer with fluoropyrimidine-based chemotherapy, only when targeted treatment or immunotherapy is unsuitable.
ER+/HER2- advanced breast cancer with emergent ESR1 mutation, with a CDK4/6 inhibitor; 20 Jul 2026
HR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026)
PTEN-deficient metastatic prostate cancer with abiraterone
Untreated locally advanced non-small-cell lung cancer unsuitable for definitive chemoradiation, or metastatic disease, with PD-L1 in 1 percent or more of tumour cells and no EGFR o...
With teclistamab after ≥1 line (MajesTEC-3); high-risk smouldering myeloma (AQUILA)
Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or in adults who are not candidates for multiagent systemic therapy.
Adults with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor-based therapy.
Newly diagnosed AML, unfit for intensive induction, with venetoclax (ASCERTAIN-V)
Accelerated approval: stage II/III locally advanced rectal cancer that is MSI-high or dMMR (FDA, 19 October 2026)
High-risk NMIBC with BCG
First-line BRAF V600E mCRC with cetuximab and chemotherapy
Metastatic colorectal cancer with a BRAF V600E mutation. Traditional approval granted 24 February 2026, converting the accelerated approval.
PET to differentiate recurrent or progressive glioma from treatment-related change, with other diagnostic evaluations, in adults and children 1 month and older.
MRI of lesions with abnormal vascularity in the central nervous system and the body. NDA 219627; Bayer
HR+/HER2- advanced breast cancer after CDK4/6 inhibitor (July 2026)
Multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, with subcutaneous daratumumab and dexamethasone (Zenbexus, label effe...
ESR1-mutant ER+/HER2- mBC; 9 Jan 2026
Subcutaneous formulation (Sarclisa Escena)
Recurrent or metastatic nasopharyngeal carcinoma after platinum-based chemotherapy and PD-1 or PD-L1 inhibitor therapy.
Recurrent or metastatic oesophageal squamous cell carcinoma after platinum-based chemotherapy and PD-1 or PD-L1 inhibitor therapy.
Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with amivantamab.
Previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026
Generic of Lutathera, whose label covers somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (ANDA 217060, Bravnetsa, approved 21 September 2026).
Label expansion (July 2026)
BCG-unresponsive NMIBC with CIS; 28 May 2026 (conditional). Conditional marketing authorisation
Resectable non-small-cell lung cancer at high risk of recurrence without an EGFR mutation or ALK rearrangement: neoadjuvant with platinum chemotherapy then adjuvant alone.
Untreated advanced classical Hodgkin lymphoma with AVD, age ≥12
BCG-unresponsive NMIBC with CIS, with BCG; 16 Feb 2026 (conditional). Conditional marketing authorisation
With BCG, BCG-unresponsive non-muscle invasive bladder cancer, carcinoma in situ no longer required (expanded indication; FDA, 14 October 2026)
Companion diagnostic for pembrolizumab in MSI-high solid tumours
Companion diagnostic for sevabertinib in NSCLC with HER2 activating mutations
Locally advanced pancreatic cancer with chemotherapy
Unresectable stage III EGFR mutation-positive non-small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy.
HR+/HER2+ advanced breast cancer maintenance with anti-HER2 and endocrine therapy
Companion diagnostic for nivolumab in oesophageal squamous cell carcinoma and gastric, GEJ and oesophageal adenocarcinoma (CPS 1 or more)
Traditional approval: unresectable or metastatic TMB-high (at least 13 mut/Mb) solid tumours after prior treatment, also as Keytruda Qlex (FDA, 16 October 2026)
Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
Pylarify TruVu formulation
Previously untreated CLL or SLL with no known 17p deletion (FDA, 2 October 2026)
Blastic plasmacytoid dendritic cell neoplasm
Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel
Erythrocytosis in adults with polycythaemia vera
First-line unresectable locally advanced or metastatic TNBC in patients who are not candidates for PD-1 or PD-L1 inhibitor therapy (ASCENT-03); listed in the EMA therapeutic indica...
First-line adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy; monotherapy.
First-line adults with unresectable locally advanced or metastatic TNBC, PD-L1 CPS at least 10 by an FDA-authorized test, with pembrolizumab or pembrolizumab/berahyaluronidase alfa...
Adults with unresectable or metastatic HR-positive/HER2-negative breast cancer after endocrine therapy and at least one chemotherapy line in advanced disease.
Label update (July 2026)
Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide. TA1167, published 18 June 2026 (ASTRUM-005); must be funded in England within 90 days of publicati...
Acquired hypothalamic obesity in adults and children aged 4 years and older. Approved 19 March 2026 (Drugs@FDA supplement 9) on the TRANSCEND trial
Colorectal cancer screening in average-risk adults aged 45 and older
Relapsed/refractory mantle cell lymphoma after ≥2 lines including a BTK inhibitor (accelerated)
With enzalutamide, metastatic androgen pathway modulation-naive or -sensitive prostate cancer with HRR gene mutations (FDA, 26 October 2026)
ES-SCLC after platinum-based chemotherapy; 29 May 2026
Relapsed/refractory myeloma after ≥1 prior therapy
Relapsed/refractory paediatric low-grade glioma (conditional)
HER2-low metastatic or unresectable breast cancer after chemotherapy in the metastatic setting, or recurrence during or within 6 months of adjuvant chemotherapy: NICE TA1197 (7 Oct...
Early-stage HER2+ breast cancer (neoadjuvant and post-neoadjuvant)
With trastuzumab and pertuzumab, maintenance after induction for unresectable or metastatic HER2-positive breast cancer (FDA, 7 October 2026)
Companion diagnostic for capivasertib in metastatic hormone-sensitive prostate cancer with PTEN loss
ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after endocrine therapy
Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)
HER2-positive (IHC 3+) unresectable locally advanced or metastatic biliary tract cancer after at least one line of systemic treatment; MHRA 19 February 2026, NICE TA1153 published...
NRG1-fusion cholangiocarcinoma
ROS1+ NSCLC (July 2026)
First-line HER2-mutant non-squamous NSCLC
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Rolling BLA initiated; completion expected Q4 2026
First-line metastatic phase 3 missed its primary PFS endpoint (Regeneron release)
BLA submitted by Summit for EGFR-mutant NSCLC after TKI (HARMONi)
EPCORE DLBCL-1 topline: PFS met, OS (US primary endpoint) not met
newly diagnosed multiple myeloma. FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamet...
Final PMA module submitted
Resubmission accepted; PDUFA 23 July 2026
BLA accepted; PDUFA 27 December 2026
Positive topline phase 2 FOURLIGHT-1
Adults with unresectable or metastatic HR-positive/HER2-negative breast cancer after endocrine therapy and at least one chemotherapy line in advanced disease; date is the announcem...
platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. FDA approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase...
Acalabrutinib + venetoclax fixed duration (AMPLIFY)
NDA accepted (evERA, ESR1-mutant)
Adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.
In combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Positive interim phase 3 in pretreated TNBC (BL-B01D1-307) announced; regulatory submissions follow
Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutatio...
First-line advanced classical Hodgkin lymphoma with AVD, age ≥12 (SWOG S1826)
sBLA for frontline high-risk DLBCL (frontMIND) planned H1 2026
Withdrawn over secondary haematologic malignancies
Programme deprioritised after regulatory feedback on Duravelo-2 design
Teclistamab + daratumumab after ≥1 prior line
Adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and...
persevERA primary endpoint not met
Pylarify TruVu formulation
For the treatment of classical Hodgkin Lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab...
Treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: Autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin...
platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor anta...
Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Confirmed: the accelerated approval of 2020 converted to traditional approval 5.7 years after it...
FDA Breakthrough Device designation for TOBY's urine-based multi-cancer early detection test (company announcement, as reported)
ODAC voted 6-3 against (clinical relevance of ctDNA-triggered switch)
Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after...
FDA clearance: first digital-pathology-based risk stratification tool for early HR+/HER2- breast cancer
ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. FDA approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader...
advanced, unresectable or metastatic cholangiocarcinoma. FDA approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic...
With venetoclax in newly diagnosed unfit AML
newly diagnosed acute myeloid leukemia. FDA approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of...
Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibito...
adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease. FDA approved atezolizumab (Tecentriq, Genentech, Inc.
fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer. FDA approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate ind...
Unresectable/metastatic TNBC when PD-1/PD-L1 therapy is unsuitable; supporting TROPION-Breast02 tested first-line disease
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy
FDA Breakthrough Device designation for SPOT-MAS 10 (company announcement)
High-risk non-muscle-invasive bladder cancer with BCG (POTOMAC)
Capivasertib approved for use with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer (CAPItello-281); abiraterone itself was already approved
Adjuvant clear-cell RCC with pembrolizumab (LITESPARK-022)
PTEN-deficient metastatic prostate cancer with abiraterone (CAPItello-281)
Adjuvant RCC with belzutifan (LITESPARK-022)
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Treatment of head and neck cancer. EMA orphan designation EU/3/26/3253 for head and neck cancer, sponsor Curadel Surgical Innovations B.V.
Treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who ha...
Maintenance in HR+/HER2+ advanced breast cancer with anti-HER2 and endocrine therapy (PATINA)
First-line PD-L1+ TNBC with sacituzumab govitecan (ASCENT-04)
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
First-line advanced TNBC monotherapy when PD-1/PD-L1 therapy is unsuitable, or with pembrolizumab/pembrolizumab-berahyaluronidase alfa when PD-L1 CPS is at least 10 by an FDA-autho...
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq (Tregzi, Orca Bio) on the Precision-T trial
Subcutaneous on-body injector
Commissioner's National Priority Voucher (CNPV) awarded
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
Third CRL, again cGMP
Muscle-invasive bladder cancer with pembrolizumab, with or without berahyaluronidase alfa
Muscle-invasive bladder cancer with enfortumab vedotin, as pembrolizumab or pembrolizumab with berahyaluronidase alfa
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
HR+/HER2- advanced breast cancer after CDK4/6 inhibitor with palbociclib and fulvestrant (VIKTORIA-1)
Gedatolisib with fulvestrant, with or without palbociclib, HR+/HER2- advanced breast cancer (VIKTORIA-1)
Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alt...
Formulation: Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no sat...
NDA 220910 received by the FDA on the RASolute 302 result
ROS1+ NSCLC after at least one prior ROS1 TKI (ARROS-1)
Treatment of ovarian cancer. EMA orphan designation EU/3/26/3258 of cabazitaxel for ovarian cancer, sponsor Nadeno Nanoscience AS (the company's product PACAB-002)
XPORT-EC-042 misses primary endpoint; endometrial development deprioritised
PSMA+ metastatic hormone-sensitive prostate cancer with ARPI (PSMAddition)
Accelerated approval of vusolimogene oderparepvec in combination with nivolumab, unresectable advanced cutaneous melanoma
In combination with nivolumab for treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (...
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
In combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of thera...
Phase 3 INTerpath-001 met RFS and DMFS endpoints; filings to follow
treatment of acute myeloid leukemia. FDA orphan drug designation for acute myeloid leukaemia, granted to SillaJen Inc.
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma
First-line HER2-positive gastric, gastro-oesophageal junction or oesophageal adenocarcinoma with tislelizumab and fluoropyrimidine-platinum chemotherapy
NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent sys...
treatment of malignant glioma. FDA orphan drug designation for malignant glioma, granted to Biomed Valley Discoveries for a reversible, ATP-competitive ERK1/2 inhibitor; the record...
PDUFA goal date for GEP-NET indication
US label lists "Metastatic Small Cell Lung Cancer - Accelerated Approval Indication Removed (1.2) 09/2026"
In combination with cetuximab for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic colorectal cancer who have been previously treated with fluo...
In combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth fac...
Treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activati...
With imlunestrant, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
With abemaciclib, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
treatment of malignant glioma. FDA orphan drug designation for malignant glioma, granted to Ever Supreme Bio Technology for allogeneic gamma delta T cells with an HLA-G CAR and a s...
FDA approval of ANDA 217060 (Bravnetsa), Lantheus Medical
treatment of soft tissue sarcoma, including rhabdomyosarcoma. FDA orphan drug designation for soft tissue sarcoma, including rhabdomyosarcoma, granted to UTR Therapeutics
FDA Molecular and Clinical Genetics Panel meeting
Previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement (REFOCUS)
With lenvatinib, advanced renal cell carcinoma with a clear cell component
With belzutifan, advanced renal cell carcinoma with a clear cell component
as a diagnostic for the management of hepatocellular carcinoma (HCC). FDA orphan drug designation of indocyanine green as a diagnostic in hepatocellular carcinoma, granted to Renew...
previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. FDA approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously unt...
treatment of pancreatic cancer. FDA orphan drug designation for pancreatic cancer, granted to SK Life Science for actinium-225 chelated with the NTSR1-targeting ligand SKL35500
treatment of gastric cancer. FDA orphan drug designation for gastric cancer, granted to T-E Meds for a trastuzumab-MMAF/exatecan dual-payload antibody-drug conjugate
the maintenance treatment of HER2-positive breast cancer. FDA approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for th...
Stage III mismatch repair deficient colon cancer. FDA approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant tre...
FDA Breakthrough Device designation for Natera's multi-cancer early detection assay (company announcement)
nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. FDA approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indire...
pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication.
locally advanced rectal cancer. FDA granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsate...
treatment of soft tissue sarcoma. FDA orphan drug designation for soft tissue sarcoma, granted to VitsGen Therapeutics
metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations.
treatment of acute myeloid leukemia. FDA orphan drug designation of cantrixil for acute myeloid leukaemia, sponsor Vivesto AB
PDUFA target date
Full approval in first-line BRAF V600E mCRC with OS benefit
Optune Pax, locally advanced pancreatic cancer with chemotherapy (PANOVA-3)
Platinum-resistant PD-L1+ ovarian cancer
Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel
Relapsed/refractory myeloma after ≥1 prior line, with daratumumab (MajesTEC-3)
First-line HER2-mutant non-squamous NSCLC
Label extended to patients aged 12 and older
Adjuvant ctDNA-positive muscle-invasive bladder cancer (IMvigor011): first ctDNA-guided indication
Used to select ctDNA-positive patients in the first ctDNA-guided drug approval (IMvigor011, atezolizumab)
Early-stage HER2+ breast cancer: neoadjuvant (DESTINY-Breast11) and post-neoadjuvant residual disease (DESTINY-Breast05)
Displaced post-neoadjuvantly by T-DXd approval (DESTINY-Breast05)
ESR1-mutated ER+/HER2- advanced breast cancer after endocrine therapy: first PROTAC approved
NRG1-fusion cholangiocarcinoma
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
1 row recategorised. Anchored to Approval of trastuzumab deruxtecan for residual disease after neoadjuvant therapy, 2026 (DESTINY-Breast05).
The year reported on trial records, with the headline result the record gives.
Registry record NCT05609370; no result is recorded here.
Registry record NCT05608044; no result is recorded here.
Registry record NCT05673785; no result is recorded here.
Registry record NCT05388669; no result is recorded here.
Registry record NCT04497844; no result is recorded here.
Registry record NCT04194775; no result is recorded here.
Registry record NCT03742102; no result is recorded here.
Registry record NCT03899792; no result is recorded here.
Registry record NCT04351555; no result is recorded here.
Registry record NCT06099782; no result is recorded here.
Objective response 64 percent after platinum chemotherapy and 85 percent in previously untreated RET fusion-positive non-small-cell lung cancer; intracranial response 91 percent.
Registry record NCT05625399; no result is recorded here.
Registry record NCT04810078; no result is recorded here.
Registry record NCT06390995; no result is recorded here.
Registry record NCT05327530; no result is recorded here.
Registry record NCT03744715; no result is recorded here.
Registry record NCT05197426; no result is recorded here.
Registry record NCT02773030; no result is recorded here.
Registry record NCT04765059; no result is recorded here.
Registry record NCT04225117; no result is recorded here.
Registry record NCT04980222; no result is recorded here.
Registry record NCT06101134; no result is recorded here.
Registry record NCT05456191; no result is recorded here.
Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.
Primary DFS endpoint not met.
Registry record NCT04717414; no result is recorded here.
CR 41.6%; median time to CR 2 months.
Primary endpoint (sustained cCR at 12 months) met; rates pending congress presentation.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Registry record NCT05440786; no result is recorded here.
Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).
Co-primary endpoints including OS met (July 2026); numbers pending.
At the final analysis (median follow-up 38.5 months) overall survival favoured perioperative tislelizumab (hazard ratio 0.65, 95 percent confidence interval 0.45 to 0.93, p=0.009)...
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not ye...
Stopped early; primary endpoint not met.
Registry record NCT03742895; no result is recorded here.
Registry record NCT04655976; no result is recorded here.
PFS HR ~0.70 (interim); OS immature.
PFS HR 0.74; OS HR 0.96 (NS).
Registry record NCT04895722; no result is recorded here.
No grade 2 or worse FLASH-related adverse events in 10 treated patients; complete pain response in 6.
Primary PFS endpoint not met; numerical +5.1 months median PFS at the high dose.
Registry record NCT03656536; no result is recorded here.
PFS improved (HR not yet published in detail).
EFS HR 0.80 (0.62 to 1.03), p 0.083, not significant; OS HR 0.86 (0.62 to 1.19).
Interim PFS not statistically significant (May 2026); final readouts pending.
PFS 12.4 vs 8.1 months (HR 0.63-0.65); OS significantly improved.
RFS and DMFS significantly improved (HRs pending presentation).
Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).
Final progression-free survival 14.8 vs 10.7 months (hazard ratio 0.70, 95% CI 0.59 to 0.84; one-sided p<0.0001).
Primary endpoint not met (ASCO GU 2026).
DFS significantly improved vs pembrolizumab (interim; HR presented ASCO GU 2026).
Three-year progression-free survival 78 percent after high-dose chemotherapy and autologous transplant against 51 percent after non-myeloablative R-DeVIC (hazard ratio 0.43, p 0.00...
Median OS 10 vs 5 months, HR 0.54.
Registry record NCT05611632; no result is recorded here.
Registry record NCT04042831; no result is recorded here.
Registry record NCT03778229; no result is recorded here.
OS and PFS significantly improved at interim analysis; numbers per ASCO 2026 presentation.
Median overall survival 38.2 months with enzalutamide plus radium-223 against 32.6 months with enzalutamide alone (hazard ratio 0.76, 95 percent confidence interval 0.60 to 0.96, p...
PFS 33.1 vs 28.2 months, not significant.
Registry record NCT04793958; no result is recorded here.
Median overall survival 19.5 against 12.5 months (hazard ratio 0.6, p = 0.0017), with more peripheral neuropathy and more fatal infections.
OS 13.2 vs 6.7 months, HR 0.40.
Registry record ISRCTN14240288; no result is recorded here.
Registry record NCT06502977; no result is recorded here.
Registry record NCT05471843; no result is recorded here.
Registry record NCT04940052; no result is recorded here.
Registry record NCT03386513; no result is recorded here.
Registry record NCT05804045; no result is recorded here.
Registry record NCT05287113; no result is recorded here.
Second-line daraxonrasib 300 mg in 26 patients with RAS G12-mutated pancreatic cancer: objective response 35 percent, median progression-free survival 8.5 months, median overall su...
Registry record NCT03964727; no result is recorded here.
Registry record NCT05583552; no result is recorded here.
Registry record NCT07150104; no result is recorded here.
Registry record NCT07217119; no result is recorded here.
Registry record NCT07217184; no result is recorded here.
Registry record NCT07084896; no result is recorded here.
Registry record NCT07150091; no result is recorded here.
Least-squares mean change in body-mass index at 52 weeks minus 16.5% with setmelanotide vs plus 3.3% with placebo (P<0.001); hunger score change minus 2.73 vs minus 1.45 (P = 0.009...
Registry record NCT04094688; no result is recorded here.
Primary PFS endpoint not met; mPFS 12.75 vs 7.43 months (mITT) not significant.
The publication year on key paper records.
Tagawa ST, Sartor O, Piulats JM, et al. The Lancet.
Liu Y, Chu Z, Jin X, et al. European Journal of Nuclear Medicine and Molecular Imaging.
Paoli M, Galardi F, Nardone A, et al. Genome Medicine.
Mahadevan D, Parekh J, Beck JT, et al. Investigational new drugs.
Yeh CM, Yu CC, Lee AF, et al. Clinical Cancer Research.
Robert M, Kotecki N, Gomez-Roca C, et al. European Journal of Cancer.
Zhou H, Zhou Q, Guo Q, et al. Lung cancer.
Gamble S, Whiteman ZE, Peinador-Marín C, et al. Nature.
Wu YL, Majem M, John T, et al. Journal of Thoracic Oncology.
Abdelghaffar K, Hassany M, Elghazaly H, et al. Archives of Public Health.
DeWeese TL, Manzanera A, Sylvester J, et al. The Lancet Oncology.
Oberstein PE, Hecht JR, Raghav K, et al. Journal of Clinical Oncology.
Carlino MS, Kapiteijn E, Piperno-Neumann S, et al. Nature Medicine.
Cheng A, Nallu S, He L, et al. Molecular Diagnosis and Therapy.
Yang JJ, Mu Y, Wang ZH, et al. Journal of Thoracic Oncology.
Armstrong AJ, Petrylak DP, Shore ND, et al. European Urology.
Sinicrope FA, Ou FS, Arnold D, et al. New England Journal of Medicine.
Zhang L, Zhang X, Wu L, et al. The Lancet Oncology.
Li Z, Hu J, Chen J, et al. The Lancet Oncology.
Motzer RJ, McDermott R, Park SH, et al. The Lancet.
Vargas V, Cortez R, Kizub D, Youngkong S, Bayona J. Journal of Cancer Policy.
Gradishar WJ, Moran MS, Abraham J, et al. Journal of the National Comprehensive Cancer Network.
Cunningham N, Cutts RJ, Swift C, et al. JAMA Oncology.
Gizaw M, Parkin DM, Asmare S, et al. Cancer Epidemiology.
Redondo-Sánchez D, Petrova D, Bigorra J, et al. European Journal of Cancer.
Park EH, Jung KW, Choi SH, Park NJ, et al. Cancer Research and Treatment.
Guilford FT, Yu S. Integrative Medicine (Encinitas).
Fizazi K, Clarke NW, De Santis M, et al. Annals of Oncology.
Schmid P, McArthur HL, Cortés J, et al. Annals of Oncology.
Tamrakar VK, Sharma K, Singh P, et al. Cancer.
Bar V, Zundelevich A, Gavert N, et al. Journal of personalized medicine.
Zhou F, Su C, Liang W, et al. Nature Communications.
Wolpin BM, Park W, Garrido-Laguna I, et al. New England Journal of Medicine.
O'Reilly EM, Wainberg ZA, Hendifar AE, et al. New England Journal of Medicine.
Zacharia GS, Pandey U, Thartori O, et al. Cureus.
Saad F, Shore N, Vjaters E, et al. European Urology.
Schmid P, Wang HC, Lynce F, et al. Annals of Oncology.
Dent R, Shao Z, Schmid P, et al. Annals of Oncology.
Huang J, Chen G, Wang Z, et al. Journal of Thoracic Oncology.
Wu J, Li X, Gu C, et al. Signal transduction and targeted therapy.
Suter RK, Jermakowicz AM, Veeramachaneni R, et al. Nature Communications.
Powderly GE, Hassevoort K, Loy M, Balonier J, Sievers C. Cureus.
Sasieni P, Johnson P, Round T, et al. New England Journal of Medicine.
Li JJ, Zhang WJ, Zeng XH, et al. Journal of Clinical Oncology.
Tang W, Lv Y, Xie H, et al. Cancer letters.
Oh DY, Lugowska I, Stroyakovskiy D, et al. ESMO Open.
Mahalingam D, Shroff RT, Carneiro BA, et al. Nature Medicine.
Labrousse P, Russell H, Stetson D, et al. Scientific Reports.
Wen PY, Berry DA, Buxton MB, et al. Journal of Clinical Oncology.
Duan J, Gao Q, Wang Z, et al. The Innovation.
Boissiere-Michot F, Gudin-De-Vallerin A, Thezenas S, et al. Virchows Archiv.
Xin X, Miao R. Cancers.
Liu Y, Zhang Y, Lin R, et al. Signal transduction and targeted therapy.
Shao X, Tian C, Chen Z, et al. Nature Medicine.
Reck M, Patel JD, Gray JE, et al. Journal of Thoracic Oncology.
Zhou C, Greillier L, Liu G, et al. New England Journal of Medicine.
Wakelee H, Spicer JD, Gao S, et al. Annals of Oncology.
Planchard D, Jänne PA, Yang JC, et al. Lung Cancer.
Gárate-Calderón V, Kumar R, Marcelain K, et al. EBioMedicine.
Zhong J, Zhao J, Duan J, et al. The Lancet. Respiratory medicine.
Cho BC, Balaraman R, Chen HJ, et al. Nature Medicine.
Angerilli V, Gasparello J, Niero M, et al. Human Pathology.
Dieras V, Curigliano G, Martin M, et al. Journal of Clinical Oncology.
Clark M, Prathapam R, Bramlett KS, et al. Journal of Molecular Diagnostics.
Braun DA, Noel MS, Moy RH, et al. Cell reports. Medicine.
Kovalyov O, Kovalyov K, Deinichenko O, Dillner J, Arroyo Mühr LS. BMJ Global Health.
Conroy S, Keane E, Rehman B, et al. The Breast Journal.
Kapoor A, Gupta A, Sansar B, et al. JCO global oncology.
Metekoua C, Wiggill T, Tombe-Nyahuma T, Ruffieux Y, Mwansa-Kambafwile J, Kwenda S, Dhokotera TG, Bohlius J, Rohner E, Muchengeti M. Cancer Medicine.
Khattak A, Carlino MS, Meniawy T, et al. Journal of Clinical Oncology.
Yilmaz S, Göktaş B, Ateş İ, Çelik M. Journal of Applied Toxicology.
Rockwell MS, Kahn KL, Fendrick AM, Vangala S, Mafi JN. JAMA Network Open.
Le X, Passaro A, Zhao Y, et al. The Lancet Oncology.
Lu S, Liu B, Luo Y, et al. The Lancet.
Barlesi F, Yao W, Duruisseaux M, et al. Future Oncology.
Ballman KV. Journal of Clinical Oncology.
Saperstein Y, Bou Sanayeh E, Boazak P, Itani H, Moussa E, Gut T. Postgraduate Medicine.
Kaminski MF, Kalager M, Løberg M, et al. The Lancet.
Li W, Zhang Y, Fan H, et al. Journal of Clinical Oncology.
Sushentsev N, Warren AY, Colling R, et al. BJU international.
McClements J, Lee WT, Koh A, et al. British Journal of Surgery.
Illerhaus G, Ferreri AJM, Wendler J, et al. The Lancet.
Cheng R, Araujo DV. Frontiers in Oncology.
Cowzer D, Walch H, Atri P, et al. Clinical Cancer Research.
Campani C, Laurent-Puig P, Villeret F, et al. Journal of Hepatology.
Foldi J, Hogan G, Johansen Taber K, et al. Future Oncology.
Morris VK, Ciombor KK, Xiao L, et al. Journal of Clinical Oncology.
Andrade MO, Bonadio RC, Ipiña A, et al. Breast Cancer Research and Treatment.
Li J, Liu T, Yu KD, et al. JAMA Oncology.
Hauschild A, Hassel JC, Ziemer M, et al. Journal of Clinical Oncology.
Harbeck N, Modi S, Pusztai L, et al. Annals of Oncology.
Akgör U, Temiz BE, Cengiz M, et al. Vaccines.
Nicholson J, Ryan S, Malone C, et al. Radiotherapy and Oncology.
Johnston S, Martin M, O'Shaughnessy J, et al. Annals of Oncology.
Metzger O, Mandrekar S, Goel S, et al. New England Journal of Medicine.
Notini G, Galbardi B, Viale G, et al. NPJ Precision Oncology.
Murciano-Goroff YR, Hollebecque A, Heist RS, et al. Nature Communications.
Worthington C, Raitses-Gurevich M, Innamorati G, et al. International Journal of Cancer.
Agarwal N, Matsubara N, Azad AA, et al. New England Journal of Medicine.
Casarini IA, Kowalski DM, Caglevic C, et al. JCO Oncology Practice.
Nabavizadeh N, McDonnell C, Kurbegov D, et al. Nature Medicine.
Gainullin VG, Manesse M, Zhuang F, et al. Cancer Epidemiology, Biomarkers & Prevention.
Neal RD, Dolly S, Johnson P, et al. Nature Medicine.
Taplin ME, Gleave M, Shore ND, et al. New England Journal of Medicine.
Wang C, Wang W, Liu H, et al. Annals of Oncology.
Dumbrava EE, Shapiro GI, Parikh AR, et al. New England Journal of Medicine.
Lee JB, Baek S, Kim DK, et al. Journal for ImmunoTherapy of Cancer.
Matasar M, Li Z, Vassilakopoulos TP, et al. Journal of Clinical Oncology.
Machalek DA, Nyemba DC, Travill D, Petoumenos K, Mbulawa ZZA, Naidoo I, Motshwane FMM, Bamford L, Rees H, Kaldor JM, Delany-Moretlwe S, HOPE study group. Lancet Global Health.
Brenner DR, Gillis J, Demers AA, et al. CMAJ.
Cunningham N, Swift C, Cutts RJ, et al. Annals of Oncology.
Menges D, Wildisen L, Scherer T, et al.; Staehelin K. JAMA Network Open.
Pugh J, Wilkinson D, Savulescu J. Journal of Medical Ethics.
Malla M, Esmail A, Tin A, et al. ESMO Gastrointestinal Oncology.
Ma H, Li Z, Shu P, et al. Pathology, research and practice.
Hulscher N, Victory K, Thorp JA, et al. Anticancer Research.
Fournier E, Schaffar R, Staehelin K, Rouxel N, Ris F, et al. European Journal of Cancer.
Esserman LJ, Fiscalini AS, Naeim A, et al. JAMA.
Tolaney SM, de Azambuja E, Kalinsky K, et al. New England Journal of Medicine.
Fang W, Wu L, Meng X, et al. New England Journal of Medicine.
Xiong A, Yao W, Zheng W, et al. The Lancet.
Tutt A, Nowecki Z, Szoszkiewicz R, et al. Clinical Cancer Research.
Wu YL, Hochmair M, Yang Y, et al. New England Journal of Medicine.
Miller JL, van Santen HM, Phillips SA, et al. New England Journal of Medicine.
Peters S, Herbst R, Horinouchi H, et al. Journal of Clinical Oncology.
Lu S, Fang J, Yu Y, et al. Journal of Thoracic Oncology.
McClements J, Lee WT, Lucocq J, et al. HPB.
Garber JE, Cameron D, Campbell C, et al. Annals of Oncology.
Wu F, Zhang W, Zhao Y, et al. Journal of Thoracic Oncology.
Turner NC, Mayer EL, Park YH, et al. The Lancet Oncology.
Wang J, Suh JM, Woo BJ, et al. Cell Reports Medicine.
Sehn LH, Hübel K, Luminari S, et al. Lancet.
Adar L, Shachar E, Laskov I, et al. International Journal of Gynecological Cancer.
Zhao Y, Liu H, Meng X, et al. New England Journal of Medicine.
Tung NM, Robson ME, Li T, et al. Journal of Clinical Oncology.
Girard N, Goldman J, Lu S, et al. JTO clinical and research reports.
Boroni M, Costa Conteville L, Ribeiro Pinto LF, Viola JPB. The Lancet Regional Health - Americas.
Hudson-Phillips SP, Nanda A, Attia M, et al. Clinical Breast Cancer.
Browne IM, Pascual J, Cutts RJ, et al. Clinical Cancer Research.
Liu AW, Do HVM, Nguyen GH, Nguyen ND, Tran LH, et al. JCO Global Oncology.
Selvakumar B, Patkar S, Nekarakanti PK, et al. HPB.
Zhang J, Ouyang Q, Zhang Q, et al. Journal of Clinical Oncology.
Liu Y, Li D, Wu L, et al. Clinical lung cancer.
Loibl S, Park YH, Shao Z, et al. New England Journal of Medicine.
Tolaney SM, Jiang Z, Zhang Q, et al. New England Journal of Medicine.
Yao H, Zhang Q, Li H, et al. The Lancet Oncology.
Thi Ngoc Toan A, Palmer MR, Phung TL, Nguyen PT. Journal of Cancer Policy.
Yu L, Zhao L, Zeng R, et al. Theranostics.
Wang S, Zhang Q, Jiang Z, et al. ESMO Open.
Hurvitz SA, Loi S, O'Shaughnessy J, et al. Annals of Oncology.
Strickler JH, Cercek A, Siena S, et al. Nature Communications.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Pancreatic ductal adenocarcinoma. FUT3-null patients, about 10%, have median CA 19-9 of 2.4 U/mL and the same short survival as patients above 200; a value of 7 or below identifies...
Primary effusion lymphoma. Across 236 United States patients diagnosed between 2001 and 2021, five-year relative survival rose from 21 to 37 per cent and median overall survival fr...
Monomorphic epitheliotropic intestinal T-cell lymphoma. In 50 patients receiving systemic chemotherapy, a modified Newcastle regimen without methotrexate gave median progression-fr...
Chronic lymphocytic leukaemia
Neuroblastoma (paediatric)
Glioma & glioblastoma
Rectal cancer
Triple-negative breast cancer (TNBC). Iza-bren phase 3 positive (Feb 2026); FDA approves Dato-DXd and sacituzumab govitecan first line (Q2 2026).
Colorectal cancer
Gallbladder cancer. 285 incidental cancers and 516 operated patients across 24 centres, 2014 to 2022; 67.7 percent of incidental cancers had liver resection.
Metastatic hormone-sensitive prostate cancer
Extrapulmonary neuroendocrine carcinoma
Mesothelioma
Hepatocellular carcinoma
Intermediate hepatocellular carcinoma (BCLC B)
Neuroendocrine tumours
Acute myeloid leukaemia. Decitabine-cedazuridine + venetoclax approved 13 May 2026 (ASCERTAIN-V, CR 41.6%).
HR-positive / HER2-negative breast cancer
Chronic lymphocytic leukaemia. Acalabrutinib-venetoclax approved 19 February; sonrotoclax accelerated approval 13 May; CaDAnCe-304 and CELESTIAL-TNCLL enrolling.
Metastatic triple-negative breast cancer
Lung cancer (all types). Over two million people invited and 7,193 lung cancers diagnosed to March 2025, 63.1 percent at stage 1 and 12.6 percent at stage 2, with the early-stage s...
Diffuse large B-cell lymphoma
BRAF V600E-mutant colorectal cancer
Triple-negative breast cancer (TNBC). Boissiere-Michot reclassifies 367 untreated TNBCs as 38% null, 38% ultralow and 24% low, none prognostic; ultralow stays unlabelled in TNBC.
Gastric & gastro-oesophageal junction cancer
Bladder & urothelial cancer
Bladder & urothelial cancer
Colorectal cancer. The American Cancer Society reports colorectal cancer incidence rising 3 percent a year in adults aged 20 to 49 and 0.4 percent a year at 50 to 64, while falling...
Stage IIB and IIC melanoma
Stage III melanoma (after surgery)
Melanoma
Melanoma
Oesophageal cancer
Renal cell carcinoma
Buccal mucosa and gingivobuccal cancer (oral cancer in India)
Hodgkin lymphoma
Hodgkin lymphoma
Oesophageal cancer
Small-cell lung cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN). CD123 ADC (CADENZA), FDA May 2026.
Prostate cancer
Metastatic pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma. ASCO plenary and NEJM; FDA approval of daraxonrasib on 26 August 2026; Optune Pax approved; zoldonrasib combinations reported; AMPLIFY-7P vaccine...
KRAS G12C-mutant pancreatic ductal adenocarcinoma
Platinum-resistant ovarian cancer
Ovarian cancer
Ovarian cancer. First immunotherapy approval in ovarian cancer (February 2026).
Advanced melanoma (unresectable stage III and stage IV)
Polycythaemia vera (PV). FDA approval for phlebotomy-dependent polycythaemia vera.
Myeloproliferative neoplasms (PV, ET, myelofibrosis). VERIFY: hepcidin mimetic controls erythrocytosis without phlebotomy; FDA approval August 2026.
Endometrial cancer. Post-hoc TP53-wild-type subgroup hypothesis not confirmed.
Thyroid cancer
Mantle cell lymphoma
Acute lymphoblastic leukaemia. Subcutaneous blinatumomab trials (including the first in mixed-phenotype leukaemia) aim to replace continuous infusion; infant trials integrate blina...
HER2-positive breast cancer
Follicular lymphoma. Secondary haematologic malignancies; EZH2 leaves the FL armamentarium.
Epithelioid sarcoma. Ipsen withdraws tazemetostat in all indications on 9 March 2026 after the SYMPHONY-1 data monitoring committee flagged secondary haematologic malignancies (18/...
Sarcomas (soft tissue, bone, GIST)
Multiple myeloma
Multiple myeloma
Breast cancer (all types). Published 3 July 2025 and recommended from 1 January 2026. For breast the classification is unchanged; the yp classification is clarified, basing ypT on...
Triple-negative breast cancer (TNBC). Datopotamab deruxtecan first line: overall survival 23.7 vs 18.7 months.
Locally advanced unresectable pancreatic ductal adenocarcinoma
HR-positive metastatic breast cancer after CDK4/6 inhibitors
Breast cancer (all types). Published April 2026. Reserves 'variant' for molecular alterations and separates subtype from pattern, updates the HER2 reporting categories so that no m...
Cervical cancer
Endometrial cancer with no specific molecular profile
Advanced or recurrent endometrial cancer
Biliary tract cancer (cholangiocarcinoma)
Non-small-cell lung cancer
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
San Francisco, CA
Boston, MA
The funding rounds on company records, each with the source that states the figure.
$400k. NCI STTR (R41) award 1R41CA306619-01A1: Alphavirus vector-mediated expression of a connexin43 mimetic peptide in glioblastoma therapy
$4m. Led by TK & Partners; oversubscribed against a USD 4 million target
$75m
$978k. NCI SBIR (R44) award 1R44CA314796-01: Enriching and expanding tumor-reactive CD8 T-cells to treat breast cancer
$1m. NCI SBIR (R44) award 1R44CA314728-01: Intraoperative MRI-Guided Neurosurgery Robot for Enhancing Ablative Treatment of Brain Cancer
$35m. Additional equity and venture debt closed 8 July 2026, bringing the Series C total to $150 million
$25m. Co-led by OrbiMed and Qiming Venture Partners USA, with Innovation Endeavors, Benchstrength, Fusion Fund and the Cancer Breakthrough Fund.
EUR 10 million from Capital Grand-Est, FINOVAM Gestion, Fournier-Majoie Foundation, Angels Sante, new private investors and Capital Cell; USD amount not stated
EUR 40 million seed listed for 29 September 2026 in the ASGCT and Citeline Q3 2026 landscape report; the company's own release was not read
$7.8bn. $115 per share in cash plus a $5 contingent value right; implied equity value $7.8 billion; completed 28 April 2026
Oversubscribed; amount not stated in the release
$937k. NCI STTR award (R42) 2R42CA262399-02: Development of a salt-based nanomedicine for non-muscle invasive bladder cancer
$1m. NCI STTR award (R42) 5R42CA257584-03: Development of a radiation-activatable nanoparticle for lung cancer therapy
$350k. NCI STTR award (R41) 1R41CA314843-01: ATTACH: A platform for rapid and unbiased discovery of antigen-specific T cells to advance precision immunotherapy
GBP 1.5 million, co-led by Kadmos Capital and Exceptional Ventures; a further GBP 700,000 came as an Innovate UK grant
$8m. Investment and collaboration with the Guangzhou-Israel Biotechnology Fund (GIBF); amount from the release title on the company press page.
$25m. Led by Redmile, Vsquared Ventures and Kindred Capital
$400k. NCI SBIR award (R43) 1R43CA309911-01A1: Combination of a novel selective FEN1 metallonuclease inhibitor with Olaparib for the treatment of PARP-resistant ovarian cancers
$150m. 9,375,000 shares at USD 16.00 per share, prospectus dated 6 August 2026; base offering before underwriting discounts and any over-allotment
$116m. Led by an undisclosed private family fund and foundation, with Seattle Children's (the initial investor) and WRF Capital
$60m. Followed an undisclosed seed round
$13m. EUR 11 million; the release gives the USD figure
$948k. NCI SBIR Phase II (R44) award 5R44CA281555-03: An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cance...
$291k. NCI STTR (R42) award 1R42CA314789-01: CellLogic: Deep Learning Identification and Characterization of Rare Events in Fluorescent Whole Slide Imaging
$1m. NCI SBIR award (R44) 1R44CA314761-01: Advancing Site-Selective Multi-Payload HER2-Targeted Conjugates to Overcome Resistance and Boost Survival in Breast and Gastric Cancers
$220m. Led by Venrock Healthcare Capital Partners, with Fidelity, Sofinnova Partners and HBM Healthcare, alongside existing investors RA Capital Management, Forbion, Pfizer, Avego...
$1m. NCI SBIR (R44) award 1R44CA314758-01: Detection and Isolation of Circulating Myeloma Cells: Toward a Minimally-Invasive CLIA-Certified Diagnostic for Multiple Myeloma
$52m. Led by founding investor Mattias Westman; cumulative funding stated as over $185 million.
$45m. Co-led by Founders Fund and The OpenAI Startup Fund; the article is headed 2026 and the website's article list calls it the Series A.
Led by Delight Ventures with Animal Spirits, Gogin Capital, ANRI and Green Core; amount not disclosed in the release
$77m. Co-led by Taiho Ventures and Arkin Bio Capital
$300m. All-stock transaction valued at approximately 300 million US dollars; announced 2 March 2026, closed 4 May 2026
$936k. NCI SBIR (R44) award 5R44CA295189-02: CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy
$83m. GBP 61 million; the release states the USD 83 million equivalent. Led by 4BIO Capital
$400k. NCI SBIR Phase I (R43) award 1R43CA306683-01A1: Overcoming Breast Cancer Resistance with a Dual-Function Antibody Therapeutic
$2.5bn. Tender offer and merger by Servier Pharmaceuticals at 21.50 US dollars a share in cash, completed 23 April 2026; the 8-K gives aggregate consideration of approximately 2.5...
$999k. NCI SBIR (R44) award 5R44CA232879-06: DoseRT: A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification
$381m. 21,177,600 shares at USD 18.00, prospectus dated 4 February 2026; gross figure before underwriting discounts and the 30-day option on 3,176,640 further shares
$350m. 23,333,334 shares at $15.00; gross proceeds of approximately $350.0 million before underwriting discounts and expenses.
$870k. NCI SBIR award (R44) 5R44CA310518-02: CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer
Hamilton Reserve Bank made an equity investment of undisclosed size and agreed to arrange a credit line of up to USD 20 million to support 2026 product sales
$400k. NCI SBIR award (R43) 1R43CA306391-01A1: Validating the reduced immunogenicity of novel human-like asparaginases to de-risk clinical development
$107m. Co-led by GV and JJDC
$28m. Total of USD 68.7 million announced at launch in March 2026
$1m. NCI SBIR (R44) award 2R44CA281633-02A1: ADEPT-STAR therapy for high risk neuroblastoma
$1.0bn. USD 1 billion in cash, announced 8 June 2026; completion announced on the company website 29 July 2026
$979k. NCI SBIR (R44) award 1R44CA310416-01: Clinical development of the anti-fas ligand monoclonal antibody M3T01 for treatment of advanced cancers
$1m. NCI SBIR Phase II (R44) award 4R44CA310160-02: A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma
$1m. NCI SBIR award (R44) 5R44CA306565-02: A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1...
$1m. NCI STTR award (R42) 4R42CA302415-02: Maximizing GlyTR pan-cancer immunotherapy by enhancing target density
$100m. Oversubscribed; led by new investor Viking Global Investors
$1m. NCI SBIR Phase II (R44) award 5R44CA302210-02: Transforming Mammography With STARLIGHT, Imagine Scientific's Monochromatic X-Ray Imaging System
$1m. NCI SBIR award (R44) 2R44CA281523-02: Engager T cell: A Simple Solution for "Off-the-shelf" T Cell Therapy for Cancer
$1m. NCI STTR (R42) award 5R42CA287488-03: Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles
$77m. Led by The Column Group
$15m. Second close co-led by Octopus Ventures and Amplify Bio, bringing total seed financing to USD 35.1 million
$1m. NCI STTR (R42) award 4R42CA302331-02: Overcoming Immune Checkpoint Blockade Resistance in Glioblastoma with a Novel Stem Cell Biotherapeutic
EUR 5 million; led by Inveready (Inveready Biotech IV) with Xesgalicia, existing investors and the founders; no USD figure stated
$14m. Led by Company K Partners with SV Investment, Flexus Partners and existing investors including affiliates of Nextrans and Quad Investment Management; total Series A 25 millio...
$48m. Announced via Business Wire, 6 May 2026, as listed on the company news page
$3.3bn. Upfront payment of $3.25 billion; up to $7.00 billion in total including clinical, regulatory and commercial milestones; announced 20 April 2026
EUR 10 million, bringing total Series A funding to EUR 23 million; led by Remiges Ventures, co-led by LifeCare Partners, with Carma Fund joining. No USD figure stated.
$80m. Led by Alta Partners with Venrock, Foresite Capital and J. Wood Capital
$1m. NCI SBIR Phase II (R44) award 1R44CA314574-01: Optical Precision Targeting for Informed Cancer biopsy (OPTIC)
$992k. NCI SBIR (R44) award 5R44CA228920-06: Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neu...
$30m. Series A upsized from USD 60 million to USD 90 million
$38m. Oversubscribed round led by GL Ventures; the release does not name the round
$587k. NCI SBIR award (R44) 5R44CA278021-03: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies
Tranche B of EUR 6 million drawn from a European Investment Bank loan facility in April 2026
$400k. NCI SBIR (R43) award 1R43CA310118-01: Remote-Controlled PC-CAR T-Cell Therapy for Hard-to-Treat Solid Tumors
$400k. NCI SBIR (R43) award 1R43CA314526-01: Affinity-tunable Antibody Drug Conjugate (ADC) against High-Grade Serous Ovarian Cancer
Hong Kong H-share listing, dealings from 28 April 2026 at HK$27.64 per share; gross proceeds HK$1,302.7 million and net proceeds HK$1,189.0 million as stated in the allotment resul...
$1m. NCI SBIR (R44) award 5R44CA298532-02: Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer
$40m. From SV Health Investors, JJDC, Forbion, GV and Northpond Ventures; round not named
$1m. NCI SBIR award (R44) 2R44CA257624-02: Non-invasive neurosurgical planning with Random Matrix Theory MRI
$35m. Credit facility from Trinity Capital replacing a prior Madryn Asset Management facility
$28m. Led by existing investors InnovaHealth Partners and Birchview Capital with new investors OSF Ventures and Colorado University Healthcare Innovation Fund; Madryn Asset Managem...
$3m. Co-led by Lotus One Investment, VP Venture Partners and MEDIN Fund
$1m. NCI SBIR (R44) award 5R44CA306674-02: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy
$2m. Casey DeSantis Florida Cancer Innovation Fund, Florida Department of Health, for the STAR-GBM trial.
$1.1bn. USD 1.1 billion upfront plus up to USD 400 million in milestones; agreement announced 6 July 2026, completed 28 August 2026 per company website
$615k. NCI SBIR (R44) award 5R44CA295155-02: Drug development of RK-33 for breast cancer treatment
$160m. CareDx agreed to pay $160 million cash up front plus up to $100 million in revenue milestones (announced 28 April 2026); completion announced July 2026.
$181k. NCI STTR award (R41) 5R41CA306611-02: Targeted Localization and Optimized Surgical Resection for Lung Cancer
$100m. Led by founding investor Deerfield Management; closed April 2026
Led by Wuhan Optics Valley Science and Innovation Industry Investment Fund; amount not stated. The company says 2025 financing totalled nearly RMB 100 million
$50m. USD 50 million financing from OrbiMed announced 20 April 2026; the company did not name the round, labelled Series B here for schema purposes only
CHF 26 million extension, bringing the Series B to CHF 105 million in total
$1m. NCI SBIR award (R44) 1R44CA310352-01: Targeting Fatty Acid Oxidation with Etomoxir for the Treatment of Recurrent Glioblastoma
$10.6bn. Tender offer at 124 US dollars per share in cash; aggregate equity value about 10.6 billion US dollars (about 9.4 billion net of cash acquired); completed 15 July 2026
Public follow-on private placement on Euronext Oslo: NOK 286 million gross, 65 million new shares at NOK 4.40
$350m. Oversubscribed private placement completed alongside the reverse merger with Galera Therapeutics; shares began trading on Nasdaq as OBX on 4 August 2026
$405k. NCI SBIR Phase I (R43) award 1R43CA310377-01A1: OmicXScreen: AI/ML-Powered, DNA Methylation Profiling Test for Early HCC and Esophageal Cancer Detection
$306k. NCI STTR Phase I (R41) award 1R41CA310335-01: Activated GaP-32 for the Treatment of Non-Melanoma Skin Cancer
$1m. NCI SBIR award (R44) 1R44CA310037-01: STING agonist-expressing BCG to enhance bladder cancer therapy
$400k. NCI SBIR (R43) award 1R43CA306418-01A1: Stable, highly potent and safe lead peptide drug conjugate for the treatment of triple-negative breast cancer
$399k. NCI SBIR award (R44) 1R44CA298354-01A1: Neuromodulation of the Gut-Brain Axis to Treat Cancer-Associated Cachexia
$2m. NCI SBIR Phase II (R44) award 1R44CA306680-01A1: Development of Manufacturing Controls for ORL1: A Fluorescent Imaging Agent for In Vivo Molecular Imaging of Melanomas
Flexible bridge equity financing (warrants) with IRIS Capital Investment: up to 4 million new shares, gross proceeds up to about EUR 19.3 million over 24 months at the then share p...
Led by BioGenerator Ventures; amount not disclosed
$5m. Oversubscribed; investor not named
$38m. The release gives a total Series B of USD 77 million; the extension amount is the difference from the USD 39 million first close
$670m. 33,500,000 shares at USD 20.00 per share, prospectus dated 9 June 2026; figure is before underwriting discounts and any over-allotment
Listed issuer financing exemption (LIFE) unit offering: approximately CAD 6.84 million closed 5 May 2026 with a final tranche to bring the total to CAD 7.52 million; led by Paradig...
CAD 6.04 million of 3.59 percent convertible debentures maturing April 2029, including CAD 2.76 million from CEO Adrian Mendes
$315k. NCI STTR (R41) award 1R41CA302359-01A1: Low-cost technology for image-guided photodynamic treatment of oral lesions in resource-limited settings
$1m. NCI SBIR Phase II (R44) award 1R44CA314813-01: Development of a new combination therapy for pancreatic ductal adenocarcinoma treatment
PreciseOnco consortium (with Philips, IGEA, EIBIR and CIRSE) awarded EUR 14.9 million public funding from the EU Innovative Health Initiative plus EUR 9 million in-kind, EUR 23.9 m...
$520k. NCI SBIR (R44) award 5R44CA310364-02: Scaling Lymphoma Diagnosis: A Cost-Effective Gene Expression Assay for Broad Implementation
$70m. Brings total capital raised to over USD 240 million
Acquired by Cureety (Paris) in September 2026; financial terms not disclosed
$30m. Described as approximately USD 30 million, with Schooner Capital and primarily existing investors.
All shares acquired by non-profit XenoTherapeutics for about 2.20 US dollars per share in cash plus a contingent value right; total deal value not stated
$740k. NCI SBIR award (R44) 1R44CA306440-01A1: Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors
$400k. NCI STTR (R41) award 1R41CA309908-01: Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia
$1m. NCI SBIR Phase II (R44) award 1R44CA306545-01A1: Demonstrating safety and combination therapy potential of a novel nanoparticle delivery system
$35m. Stated as over USD 35 million; led by HighLight Capital with InnoPinnacle Fund and existing investors
$137m. Co-led by Frazier Life Sciences and Novartis Venture Fund; total raised to date USD 162 million
CNY 80 million, jointly from XtalPi, Songhe Capital and three other investors, per the company timeline
AUD 12 million per SmartCompany (2 October 2026); some databases report about USD 8.3 million. No USD figure from the company.
$225m. Led by RA Capital Management, with Canaan Partners and Forbion.
GBP 1.4 million, co-led by UKI2S and the Liverpool City Region Seed Fund
Nearly 40 million US dollars (近4000万美元) per the company headline, with Hillhouse, LYFE Capital, Lilly Asia Ventures and Chunhwa Ventures among investors; amountUsd omitted because...
$1m. NCI SBIR award (R44) 5R44CA278144-04: A Phase 1-2 clinical program for the treatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab...
$100m. Co-led by RA Capital, a16z Bio+Health and Nextech Invest
$740k. NCI SBIR (R44) award 5R44CA291622-03: A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
$407k. NCI SBIR (R44) award 1R44CA306688-01A1: A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients
$108m. New investors RA Capital Management, Deep Track Capital, Osage University Partners and BeOne Medicines, with OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant
$52m. Led by a16z with founding investor Omega Funds
$125m. USD 125 million plus, led by Morgan Health; valuation stated as more than USD 2 billion
$8m. Led by Kantharos Capital
$398k. NCI SBIR award (R43) 1R43CA310292-01: Development of a Universal Next Generation T Cell Receptor Cancer Therapy: Preclinical Proof-of-Concept and Optimization
$400k. NCI SBIR Phase I (R43) award 1R43CA309866-01: Development of a uPAR-Targeting Antibody-Drug Conjugate (ADC) for Pancreatic Adenocarcinoma
$1m. NCI SBIR (R44) award 1R44CA310342-01A1: Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer
$406k. NCI SBIR award (R43) 1R43CA309958-01: Overcoming Access Barriers to Cancer Clinical Trials via an Innovative Platform for Matching Patients to Trials and Resources
$3.1bn. Upfront consideration on a cash-free, debt-free basis, plus up to 1.85 billion US dollars in contingent milestones; completed 21 May 2026
$63m. Led by Insight Partners and Medical Excellence Capital; M Ventures and Pfizer Ventures co-led. Total capital raised USD 71.2 million.
$935k. NCI SBIR award (R44) 4R44CA306533-02: Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic bre...
$50m. Over USD 50 million; Series A and A+ led by Loyal Valley Capital and Decheng Capital respectively, with OrbiMed, Hankang Capital, Eisai Innovation, C&D Emerging Industry Equi...
$1m. NCI SBIR award (R44) 5R44CA281547-03: VIPCare: Virtual Predictive Care workflow with EHR integrated surveillance for optimal follow-up care management for Cancer Patients
$1m. NCI SBIR (R44) award 5R44CA302283-02: Development of a novel MYC inhibitor for cancer therapy
$400k. NCI SBIR Phase I (R43) award 1R43CA310454-01A1: Study of CB-101: A Novel First-in-Class Trispecific Antibody Targeting ROR1, EpCAM, and CD3 for the Treatment of Colorectal C...
$398k. NCI SBIR award (R43) 1R43CA310036-01A1: Development of a Pre-Targeting Strategy for Liver Cancer Radionuclide Therapy
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
European Heart Journal
Lancet Oncology
JCO Precision Oncology
The Lancet Regional Health - Americas
Gynecologic Oncology
JNCI Monographs
Lancet Global Health
Journal of Cancer Research and Practice
International Journal of Gynecological Cancer
Israel Journal of Health Policy Research
Cell
Journal of Chromatography A
European Journal of Cancer
International Journal of Cancer
Frontiers in Pharmacology
eBioMedicine
Nature Human Behaviour
European Journal of Cancer
BMJ Oncology
Annals of Internal Medicine
JCO Global Oncology
Cancer Discovery
Cold Spring Harbor Perspectives in Biology
The Lancet Regional Health - Europe
Gastroenterology
HemaSphere
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Expected date. Novartis announced the supplemental filing after the PSMAddition results in 2025. No action date has been disclosed; the year is our estimate.
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Confirmed date. PDUFA target action date stated by Nuvalent when the FDA accepted the new drug application. Nuvalent's first potential approval.
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Confirmed date. Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee reviews GRAIL's premarket approval application.
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Actual primary completion date on ClinicalTrials.gov.
Confirmed date. Europe's largest oncology congress. Watch for: TROPION-Breast05, first-line ADC + IO data, late-breaking radioligand and bispecific ADC results.
Estimated primary completion date on ClinicalTrials.gov.
Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.
Confirmed date. The breast cancer congress. Post-neoadjuvant TNBC ADC trials (ASCENT-05, TROPION-Breast03) and sac-TMT first-line TNBC data are candidates for presentation here or...
Confirmed date. Haematology's main congress: CAR-T, bispecifics, menin inhibitors, BCL-2 combinations.
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Expected date. Topline positive 19 August 2026; hazard ratios and curves expected at a late-2026 congress (ESMO or SMR), with regulatory filings to follow.
Expected date. Full results presented at ASCO 2026 (primary stage III to IV endpoint not met; stage IV reduction reported).
Expected date. All-stock deal at $16.25 per share announced July 2026; the companies guided to a close in late 2026 or early 2027.
Expected date. Primary completion per registry falls in 2026; timing of topline is our estimate. Would complete the ADC + IO first-line picture alongside ASCENT-04.